Comparison Quality of sedation with Daxmedetomidine and propofol in cardiac patients during transesophageal echocardiography

Efficiency of Daxmedetomidine and propofol in cardiac patients during transesophageal echocardiography

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016112731131N1

Enrollment

Registered

2017-03-03

Start date

2017-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart disease. Other acute rheumatic heart disease

Interventions

Intervention 1: Patients in the first group receive propofol 25-75 kg /min /µ. Intervention 2: Patients in the second group receive infusion Daxmedetomidine 0.5 µ/kg/hr .

Treatment - Drugs

Patients in the first group receive propofol 25-75 kg /min /µ.

Patients in the second group receive infusion Daxmedetomidine 0.5 µ/kg/hr .

Eligibility

Sex/Gender

All

Age

1 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria included patients who underwent elective TEE been detected. Exclusion criteria include patients who are pregnant; benzodiazepines or opioids taken in the last 24 hours; or patients who receive sedation is considered to be unstable.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Quality of sedation. Timepoint: During treatment. Method of measurement: Based on feedback from patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Rasul Azarafarin

Iran University of Medical Sciences

azarfarin@rhc.ac.ir+98 21239212017

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026